PROCTER & GAMBLE HEALTH L Latest Share Price (PGHL)
TODAY IN ONE LINE
PGHL fell 1.7% on light volume, lagging Nifty's 0.1% move.
With a market cap of ₹9,378.65 Cr., it trades at a P/E of 26.43. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
PROCTER & GAMBLE HEALTH L flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 54.6% YoY
- ●High Capital EfficiencyROCE of 92.1% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 62.3%
- ●Healthy Operating MarginsOPM is structurally strong at 32.0%
- ●Steady Dividend YieldReliable 3.45% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Promoter BuyingPromoters increased holdings by 51.82% QoQ
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 74.2% YoY
- ●Rising Receivables vs SalesReceivables grew 53.1% outpacing sales growth of -18.9%
Latest PROCTER & GAMBLE HEALTH L News
What changed recently?
Recent events, corporate actions, and announcements.
PROCTER & GAMBLE HEALTH L valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for PROCTER & GAMBLE HEALTH L, framed against the sector median so the premium or discount is obvious at a glance.
PROCTER & GAMBLE HEALTH L trades at a P/E of 26.43× and P/B of 17.98×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
PROCTER & GAMBLE HEALTH L technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for PROCTER & GAMBLE HEALTH L — derived from the latest tape, not yesterday's close.
PROCTER & GAMBLE HEALTH L last traded at ₹5,660 with an intraday range of ₹5,650–₹5,780 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹5660.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 6003.33 | +343.33 | +6.07% |
| R3 | 5873.33 | +213.33 | +3.77% |
| R2 | 5826.67 | +166.67 | +2.94% |
| R1 | 5743.33 | +83.33 | +1.47% |
| PIVOT | 5696.67 | 36.67 | 0.65% |
| CURRENT | 5660.00 | — | — |
| S1 | 5613.33 | -46.67 | -0.82% |
| S2 | 5566.67 | -93.33 | -1.65% |
| S3 | 5483.33 | -176.67 | -3.12% |
| S4 | 5353.33 | -306.67 | -5.42% |
PGHL is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹5670–₹5780
Trading Inside opening range
PROCTER & GAMBLE HEALTH L financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for PROCTER & GAMBLE HEALTH L — consolidated or standalone — with margins, YoY growth and key ratios inline.
PROCTER & GAMBLE HEALTH L reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹9,378.65 Cr. and reported EPS of ₹57.92.
PROCTER & GAMBLE HEALTH L segment analysis : revenue and profit mix.
Disclosed business segments at PROCTER & GAMBLE HEALTH L with their share of revenue and profit, switchable between consolidated and standalone reporting.
PROCTER & GAMBLE HEALTH L discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for PROCTER & GAMBLE HEALTH L.
Our AI distills the core fundamental drivers supporting PROCTER & GAMBLE HEALTH L, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
PROCTER & GAMBLE HEALTH L's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Exceptional ROE 62.32% and ROCE 92.10% substantially exceed peer medians, signaling superior capital efficiency.
Operating margin 30.76% TTM significantly outpaces peer average ~18%, demonstrating pricing power and cost control.
Fortress balance sheet with debt-to-equity 0.0000x and net cash position ₹2,890.4 Cr reflects zero refinance risk.
Latest quarterly EPS grew 54.60% YoY, reflecting robust earnings momentum and operational excellence.
Diversified OTC brand portfolio (Polybion, Evion, Neurobion, Nasivion, Livogen, Seven Seas) mitigates concentration risk.
Key Risks.
P/E ratio 32.05x elevated relative to peer median 30.34x, suggesting premium valuation despite growth.
Price-to-book 15.19x significantly above peer median 3.42x indicates stretched valuation on book basis.
5-year revenue CAGR negative −7.18% despite TTM growth 19.10%, revealing structural decline offset by cyclical recovery.
Payout ratio 78.82% constrains reinvestment capacity and limits future growth capex flexibility.
52-week price return flat 0%, stock lacks recent momentum despite strong earnings acceleration.
Flip Conditions.
Valuation risk. a P/E above 34 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 57% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 1.73%.
PROCTER & GAMBLE HEALTH L peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — PROCTER & GAMBLE HEALTH L is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
PROCTER & GAMBLE HEALTH L chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for PROCTER & GAMBLE HEALTH L — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
PROCTER & GAMBLE HEALTH L delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for PROCTER & GAMBLE HEALTH L over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in PROCTER & GAMBLE HEALTH L stood at 62.0% of traded volume, against a 20-day average of 59.6%.
PROCTER & GAMBLE HEALTH L announcements: results, concalls, ratings, M&A.
Filings PROCTER & GAMBLE HEALTH L sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
PROCTER & GAMBLE HEALTH L files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 81 documents below.
Updates
Procter & Gamble Health Limited has informed the Exchange regarding 'This is in reference to our letter dated May 26, 2026, regarding re-appointment…
Shareholders meeting
Procter & Gamble Health Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 03, 2026. Further,…
Shareholders meeting
Procter & Gamble Health Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 03, 2026
Shareholders meeting
Procter & Gamble Health Limited has informed the Exchange about Shareholders meeting
Shareholders meeting
Procter & Gamble Health Limited has informed the Exchange about Shareholders meeting
Investor decks & rating reports.
PROCTER & GAMBLE HEALTH L dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue PROCTER & GAMBLE HEALTH L has declared, sequenced by announce and record date.
PROCTER & GAMBLE HEALTH L corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About PROCTER & GAMBLE HEALTH L: business, sector, key facts.
What PROCTER & GAMBLE HEALTH L does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
PROCTER & GAMBLE HEALTH L operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: PGHL, BSE: 500126.
Procter & Gamble Health Limited (PGHL) is a prominent player in the Indian pharmaceutical and consumer healthcare market, with an established international presence. Its core business revolves around the manufacturing and marketing of a diverse range of health-related products.
The company's product portfolio is primarily focused on over-the-counter (OTC) medications, vitamins, minerals, and dietary supplements. This caters to a broad consumer base seeking self-care solutions for various health needs. These products are marketed under several well-recognized brand names, including Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas. Each brand likely targets specific segments within the healthcare market, offering specialized products to meet differing consumer demands.
PGHL's history traces back to 1967, originally operating under the name Merck Limited. The company underwent a significant rebranding in May 2019, adopting its current name to reflect its ownership under the Procter & Gamble umbrella. This change underscores the strategic alignment with the larger global Procter & Gamble corporation, leveraging its extensive resources and brand recognition for expansion and growth within the Indian and international markets.
The company's headquarters are located in Mumbai, India, strategically positioning it within a large and rapidly growing consumer market. Its status as a subsidiary of Procter & Gamble Overseas India BV further highlights its integration within the larger Procter & Gamble global network. This structure likely provides access to significant resources, technological advancements, and distribution channels, enhancing the company's competitiveness and market reach.
In summary, PGHL's business model centers on the development, production, and marketing of a diverse range of healthcare products targeting various consumer needs. Its strong brand portfolio, backed by the resources of Procter & Gamble, positions it for continued growth and success within the competitive healthcare landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about PROCTER & GAMBLE HEALTH L (PGHL).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of PROCTER & GAMBLE HEALTH L (PGHL)?
The current share price of PROCTER & GAMBLE HEALTH L (PGHL) is ₹5,660.00. Today, the stock has declined by ₹97.50 (1.69%), trading in a range of ₹5,650.00 to ₹5,780.00. The stock opened at ₹5,757.50 with a trading volume of 7,255 shares.
02Is PROCTER & GAMBLE HEALTH L stock a good investment for long-term?
PROCTER & GAMBLE HEALTH L can be considered for long-term investment based on several factors. The company has a market capitalization of ₹9,378.65 Cr., P/E ratio of 26.43, ROE of 62.32%, and ROCE of 92.1%. The dividend yield stands at 3.45%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of PROCTER & GAMBLE HEALTH L stock?
The 52-week high price of PROCTER & GAMBLE HEALTH L (PGHL) is ₹6,975.00, while the 52-week low is ₹4,707.00. Currently trading at ₹5,660.00, the stock is 20.25% above its 52-week low and 18.85% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy PROCTER & GAMBLE HEALTH L stock at the current price?
Whether to buy PROCTER & GAMBLE HEALTH L stock at ₹5,660.00 depends on multiple factors. The stock is currently trading with a P/E ratio of 26.43 and P/B ratio of 17.98. Today's performance shows a loss of 1.69%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of PROCTER & GAMBLE HEALTH L and when is the next dividend?
PROCTER & GAMBLE HEALTH L offers a dividend yield of 3.45%, which means for every ₹100 invested at the current price of ₹5,660.00, you can expect to receive approximately ₹3.45 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of PROCTER & GAMBLE HEALTH L?
PROCTER & GAMBLE HEALTH L's key financial metrics include: P/E Ratio: 26.43, P/B Ratio: 17.98, ROE: 62.32%, ROCE: 92.1%, Dividend Yield: 3.45%, EPS: ₹57.92, Book Value: ₹316.01, and Debt-to-Equity: 0. The company's market cap stands at ₹9,378.65 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is PROCTER & GAMBLE HEALTH L stock performing today in the market?
PROCTER & GAMBLE HEALTH L stock opened at ₹5,757.50 and is currently trading at ₹5,660.00, showing a decline of ₹97.50 (1.69%). The intraday high is ₹5,780.00 and low is ₹5,650.00. The trading volume stands at 7,255 shares, indicating moderate market participation today.
08What is the P/E ratio of PROCTER & GAMBLE HEALTH L and what does it indicate?
PROCTER & GAMBLE HEALTH L has a Price-to-Earnings (P/E) ratio of 26.43, which means investors are willing to pay 26.43 for every ₹1 of earnings. With an EPS of ₹57.92, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about PROCTER & GAMBLE HEALTH L (PGHL) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.